Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Lung cancer

Intragenic ERBB2 kinase mutations in tumours

Abstract

The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Similar positioning within the epidermal growth-factor receptor (EGFR) kinase domain (database accession numbers MMDB:20494/PDB:1M17) of the EGFR and ERBB2 mutations that are found in a proportion of lung tumours.

Similar content being viewed by others

Nadia Harbeck, Frédérique Penault-Llorca, … Fatima Cardoso

References

  1. Sawyers, C. L. Genes Dev. 17, 2998–3010 (2002).

    Article  Google Scholar 

  2. Paez, J. G. et al. Science 304, 1497–1500 (2004).

    Article  ADS  CAS  Google Scholar 

  3. Lynch, T. J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).

    Article  CAS  Google Scholar 

  4. Futreal, P. A. et al. Nature Rev. Cancer 4, 177–183 (2004).

    Article  CAS  Google Scholar 

  5. Slamon, D. J. et al. Science 235, 177–182 (1987).

    Article  ADS  CAS  Google Scholar 

  6. Klapper, S. et al. Adv. Cancer Res. 1, 25–79 (2000).

    Google Scholar 

  7. Hirsch, F. R. & Langer, C. J. Semin. Oncol. 31, 75–82 (2004).

    Article  CAS  Google Scholar 

  8. Rosell, R. J. Clin. Oncol. 22, 1171–1173 (2004).

    Article  ADS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. Andrew Futreal.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stephens, P., Hunter, C., Bignell, G. et al. Intragenic ERBB2 kinase mutations in tumours. Nature 431, 525–526 (2004). https://doi.org/10.1038/431525b

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/431525b

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing